Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN66987216
ISRCTN66987216
Completed
未知

A randomised, double-blind, placebo-controlled, two-phase study on the impact of Doxycycline on fear memory in healthy individuals

Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)0 sites160 target enrollmentJune 23, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)
Enrollment
160
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/28373691 results (added 09/07/2019) 2019 Results article in https://pubmed.ncbi.nlm.nih.gov/31615840/ (added 10/07/2023)

Registry
who.int
Start Date
June 23, 2015
End Date
July 27, 2018
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)

Eligibility Criteria

Inclusion Criteria

  • •1\. Informed consent as documented by signature
  • •2\. Age 18 – 40 years

Exclusion Criteria

  • •1\. Allergy to Doxycycline or to any other ingredient in the named drug
  • •2\. Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
  • •3\. Women who are pregnant or breast feeding
  • •4\. Intention to become pregnant during the course of the study
  • •5\. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, combined with a mechanical contraceptive (condom, diaphragm)
  • •6\. Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
  • •7\. Any history of psychiatric, neurological, dependence or systemic/rheumatic disease
  • •8\. Known or suspected non\-compliance, drug or alcohol abuse
  • •9\. Inability to follow the procedures of the study, e.g. due to language problems
  • •10\. Participation in another study with investigational drug within the 30 days preceding and during the present study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Effect of concomitant treatment with an androgen on sexual functioning in women using an oral contraceptio
ISRCTN03247616Pantarhei Bioscience BV (Netherlands)81
Completed
Not Applicable
Studying the impact of Lorazepam on approach/avoidance behaviour in healthy individuals
ISRCTN12590498Psychiatric University Hospital (Psychiatrische Universitätsklinik) Zürich (PUK ZH)60
Completed
Not Applicable
A double blind, randomised, placebo controlled, multicentre trial of Anti-Tumour Necrotising Factor alpha (Anti-TNFa) chimeric monoclonal antibody (infliximab, Remicade®) in combination with methotrexate in patients with very early inflammatory arthritisEarly inflammatory arthritisMusculoskeletal DiseasesArthritis
ISRCTN21272423Medical University of Vienna (Austria)89
Completed
Phase 2
Phase II/III Oxabact™ Study
ISRCTN63711065OxThera IP AB (Sweden)35
Completed
Phase 2
Study to evaluate the safety and efficacy of CCX168 in subjects with renal vasculitis on background cyclophosphamide treatmentRenal VasculitisCirculatory SystemRenal vasculitis
ISRCTN53663626ChemoCentryx, Inc. (USA)60